Yungjin Pharm Transfers Japan Rights to KL1333 to Pharming Technologies

By Public Technologies
  • Yungjin Pharm’s Nov. 5, 2026, correction disclosed the transfer of Japanese rights to KL1333 to Pharming Technologies under a supplemental agreement.
  • Pharming now holds worldwide rights outside South Korea; the agreement also expands the scope of licensed technology.
  • The Japanese rights transfer carries additional upfront, milestone and royalty payments, excluded from the existing $3 million upfront and $54 million milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yungjin Pharm. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261105800299), on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk